Skip to main content
Journal of Virology logoLink to Journal of Virology
. 2000 Mar;74(6):2694–2702. doi: 10.1128/jvi.74.6.2694-2702.2000

Replication of Lengthened Moloney Murine Leukemia Virus Genomes Is Impaired at Multiple Stages

Nam-Hee Shin 1, Dennis Hartigan-O'Connor 2, Julie K Pfeiffer 1, Alice Telesnitsky 1,*
PMCID: PMC111759  PMID: 10684285

Abstract

It has been assumed that RNA packaging constraints limit the size of retroviral genomes. This notion of a retroviral “headful” was tested by examining the ability of Moloney murine leukemia virus genomes lengthened by 4, 8, or 11 kb to participate in a single replication cycle. Overall, replication of these lengthened genomes was 5- to 10-fold less efficient than that of native-length genomes. When RNA expression and virion formation, RNA packaging, and early stages of replication were compared, long genomes were found to complete each step less efficiently than did normal-length genomes. To test whether short RNAs might facilitate the packaging of lengthy RNAs by heterodimerization, some experiments involved coexpression of a short packageable RNA. However, enhancement of neither long vector RNA packaging nor long vector DNA synthesis was observed in the presence of the short RNA. Most of the proviruses templated by 12 and 16 kb vectors appeared to be full length. Most products of a 19.2-kb vector contained deletions, but some integrated proviruses were around twice the native genome length. These results demonstrate that lengthy retroviral genomes can be packaged and that genome length is not strictly limited at any individual replication step. These observations also suggest that the lengthy read-through RNAs postulated to be intermediates in retroviral transduction can be packaged directly without further processing.


Regardless of whether a particular type of retrovirus encodes only Gag, Pol, and Env or if it also encodes additional proteins, most replication-competent retroviral genomes are fairly similar in length—roughly 8 to 9.5 kb long—with only a few outliers such as the 12.3-kb walleye dermal sarcoma virus (15). This suggests that there may be a selective advantage for retroviruses to maintain relatively small genomes, a notion supported by the observation that most acute transforming retroviruses acquired host-derived oncogenes at the expense of essential viral coding regions rather than by lengthening their genomes (23).

It has been suggested that retroviral genome size is limited at the level of RNA packaging (10). Although some replication-competent retroviral vectors with inserted sequences are fairly stable (notably some in which the src region of Rous sarcoma virus [RSV] is replaced by heterologous sequences [26]), the observation that sequences added to other replication-competent retroviruses are rapidly deleted during virus passage has been cited as evidence for an upper size limit to packageable retroviral RNAs (10, 20). However, these later findings do not exclude the possibility that the additional sequences may have been lost simply because there was no advantage in retaining them, or that size limitations may be imposed at replication stages other than packaging. In studies that examined the RNAs encapsidated by an RSV derivative with a defective polyadenylation signal, most encapsidated RNAs were not significantly longer than standard genome length (14). Although differences in cellular and virion RNA populations were not explored in that study, these findings were interpreted as suggesting that longer read-through RNAs were specifically excluded from encapsidation (14).

Retroviruses copackage two complete copies of their genomes joined together in a noncovalent dimer linkage structure (2). Numerous genetic studies have shown that retroviruses can copackage two RNAs that differ significantly from one another if the RNAs retain compatible packaging and dimerization regions. Retroviruses can even copackage a normal genome-length RNA with a much shorter RNA (16). Experimental evidence suggesting that two RNA dimers—a total of four RNAs—can be coencapsidated when viral RNAs are short (32) is consistent with the notion that retroviruses have fairly fixed packaging capacities which can be reached in ways other than the copackaging of two same-length RNAs.

It is not clear why maintaining a two-RNA genome is advantageous for retroviruses. Genetic studies have demonstrated that whereas both retroviral RNAs can and often do participate in DNA synthesis, a single RNA is sufficient to template retroviral DNA (17). Although packaging may precede dimerization for at least some kinds of retroviruses (reference 24 and citations therein), the close genetic linkage between genome regions implicated in dimerization and in packaging has been suggested to reflect that the dimer may serve principally to provide the RNA structure required for specific RNA encapsidation (30). A corollary of this suggestion is that any RNA which could form a dimer with a viral RNA might facilitate packaging of the viral RNA. Experiments in this report tested the notion that if packaging capacity were determined by the total mass of RNA in a virion rather than by the length of individual RNAs, then the packaging maximum could be reached by copackaging two different-length RNAs, one of which could be much longer than the native genome. The findings were not consistent with this initial hypothesis but did demonstrate that lengthy RNAs can be encapsidated into murine leukemia virus (MLV) virions.

MATERIALS AND METHODS

Plasmid construction.

Dystrophin cDNA-containing gag-pol-puromycin gene (puro) expression plasmid pGPP (also known as pNH 133-11) has been described elsewhere (27). The version of pGPP used here (pD1012-9) differed from pNH 133-11 by the inclusion of a polylinker between Moloney MLV (M-MLV) sequences and the simian virus 40 promoter. This polylinker, which introduced EcoRI, BclI, AscI, BstBI, NgoMI, and SmaI/XmaI sites, was introduced by digesting a double-stranded oligonucleotide of sequence 5′ CGGAATTCTGATCAGGCGCGCCTTCGAAGCCGGCCCGGGCAATTGGGGA with EcoRI and MfeI and then ligating this into EcoRI-cleaved pNH 133-11. Murine dystrophin cDNA fragments of 3.86, 7.86, and 11.06 kb were generated by PCR from A1F1 (19), which contains the intact ∼14-kb murine dystrophin cDNA, and inserted into the polylinker of pD1012-9. The oligonucleotides used to amplify dystrophin sequences were engineered to contain XmaI sites at their termini; PCR products were digested with XmaI and inserted into the NgoMI site of pD1012-9. All dystrophin PCR fragments shared a common 5′ end (starting in the fourth codon of the dystrophin coding region) and differed in their 3′ ends: the 3′ end of dystrophin sequences in pGPP+4 was 5′ AGAGAAAGCAAAC, in pGPP+8 it was 5′ GATCACAGAAACC, and in pGPP+11 it was 5′ GGAAGCCTTTTCC. Dystrophin PCR products were not sequenced, and no attempt was made to express the gene segments as proteins.

+hyg (pNH 359-2) contains upstream long terminal repeat and packaging site regions of pBabe-puro and a PGK promoter, hygromycin B phosphotransferase coding sequences, herpes simplex virus thymidine kinase polyadenylation signal, and pUC19 plasmid backbone sequences (21). It was constructed by ligating together a 1.8-kb BamHI-ScaI fragment of pBabe-puro and a 2.1-kb fragment of pPGK-hygro into a ScaI-HindIII vector fragment of pUC19.

The RNA probe plasmid pD1040-2 was a derivative of pBluescript SK II+ (Stratagene) containing a 330-bp MscI-BsrBI fragment from the matrix region of MLV gag. pB481-7 was a derivative of pBluescript SK II− that contained a 442-bp SacII-ClaI fragment of the puromycin gene.

MLV, which contains a packaging sequence deletion between M-MLV nucleotides 215 and 368, has previously been described (27).

Animal cells and viruses.

D17 and NIH 3T3 cells and their derivatives were grown in Dulbecco's modified Eagle's medium supplemented with 10% calf serum (Gibco). ET cells (a 293T-based line that expresses ecotropic env) (27) and derived cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (HyClone). Puromycin-resistant ET, D17, and 3T3-derived cells were selected in 1, 2, or 6 μg, respectively, of puromycin (Sigma) per ml.

NIH 3T3 cells that constitutively express gibbon ape leukemia virus (GaLV) envelope (Env) were generated by transfection with pJP49-2, a plasmid containing GaLV env (41) driven by the PGK promoter of pPNT (37) with a histidinol resistance gene from pSV2his (13). pJP49-2 was transfected into NIH 3T3 cells by using Lipofectamine (Gibco/BRL) according to the manufacturer's instructions. At 48 h after transfection, cells were selected in medium containing 5 mM l-histidinol (Sigma). Histidinol-resistant colonies were single cell cloned, and several individual clones were functionally tested for the ability to supply GaLV Env in trans by transiently transfecting them with pGPP and then testing the resulting virus for the ability to confer puromycin resistance to 293T or D17 cells. The cell clone that produced the highest puromycin-resistant titer was used in subsequent experiments.

Virion proteins were quantified by performing quantitative reverse transcriptase assays as described elsewhere (31). All values were confirmed by assaying more than one concentration of enzyme, and all samples used were at least 10-fold above uninfected mock culture medium values and were within the linear range of the assay. All virions in this study should be formed of identical Gag-Pol precursors, and hence the quantitative reverse transcriptase assay is as good a way to standardize virion protein content here as measuring a Gag protein would be. Note that relative amounts, not absolute molar amounts, of protein were determined.

Transient transfections were performed by the calcium phosphate method as previously described (27), using ∼60% confluent cells. Within each experiment, all plates were transfected with the same mass of plasmid DNA (10 μg per 60-mm-diameter plate) and also with molar equivalents of pGPP or derivative. Because the mass per mole of the larger derivatives is greater than that for pGPP, appropriate amounts of pUC19 DNA were added as carrier DNA as necessary. Plasmids were propagated in the Stbl2 strain of Escherichia coli (Gibco/BRL), purified using Qiagen plasmid maxi kits, and quantified by UV spectrophotometry. Transfection efficiency tests were performed by including 0.125 μg of the cytomegalovirus promoter-driven lacZ expression plasmid pCH 110 (12) in transfection mixtures for parallel control plates and then staining for lacZ expression using standard procedures (29) 48 h posttransfection. The fraction of cells which took up plasmid DNA varied by less than a factor of 2 among plates in each experiment. Controls in which ET cells were transfected with pCH 110 serially diluted with pUC19 suggested that at least 20 to 100 plasmids were cotransfected into individual cells under the conditions used, and hence virions produced during cotransfection experiments were formed in cells which coexpressed GPP and Ψ+hyg.

Infections were performed in the presence of 8 μg of Polybrene (hexadimethrine bromide; Sigma) per ml for 2 h at 37°C. Titers were determined by endpoint dilution. Puromycin was added directly to infected cells without cell passage. Well-separated puromycin-resistant colonies were selected and expanded for study as clonal integrants.

Purification and analysis of viral nucleic acids. (i) Cellular RNA.

At 48 h posttransfection, medium was removed by aspiration and 1 ml of Trizol reagent (Gibco/BRL) was added to each 60-mm-diameter plate of cells. Subsequent steps were performed according to the manufacturer's instructions. Samples were suspended in 100 μl of a mixture containing 25 mM Tris-Cl (pH 8), 50 mM MgCl2, 5 mM dithiothreitol, 1.5 U of RNase-free DNase (Boehringer Mannheim Biochemicals [BMB]) per ml, and 0.5 U of RNasin (BMB) per ml, incubated 15 min at 37°C, and then stopped by addition of 25 μl of 50 mM EDTA–1.5 M sodium acetate (pH 4.5)–1% sodium dodecyl sulfate (SDS). Samples were extracted with an equal-volume mixture of phenol plus chloroform-isoamyl alcohol (24:1, vol/vol) and ethanol precipitated. Dried pellets were resuspended in diethyl pyrocarbonate-treated distilled H2O.

Controls to ensure that DNase treatment reduced transfected plasmid DNA in RNA preparations to below Northern blot or RNase protection assay detection levels involved processing samples from parallel experiments in which cells were transfected with plasmids that contained probe-complementary sequences but which lacked polymerase II promoters.

(ii) Viral RNA purification.

Virus-containing medium was collected and filtered every 12 h starting 24 h posttransfection and centrifuged at 500,000 × g in a Sorvall RC M120EX ultramicrocentrifuge for 25 min at 4°C. Pellets were suspended in 200 μl of 50 mM Tris (pH 7.5)–10 mM EDTA–1% SDS–100 mM NaCl–50 μg of tRNA/ml–100 μg of proteinase K/ml. Where appropriate, recovery marker RNA (see below) was added. Samples were incubated at 37°C for 30 min, extracted with phenol plus chloroform-isoamyl alcohol (24:1, vol/vol), and ethanol precipitated; they were then DNase treated and processed as described for cellular RNA.

RNA probes were prepared by cleaving pD1040-2 with EcoRI and transcribing with T3 RNA polymerase or by cleaving pB481-7 with BssHII and transcribing with T7 RNA polymerase. The pD1040-2 406-base runoff transcript protects 330 bases of gag sequences when annealed to wild-type MLV RNA, while the 237-base pB481-7 runoff transcript protects 194b of puro RNA. Cleavage of pD1040-2 with BsrGI and divergent transcription with T7 RNA polymerase yielded recovery marker RNA. In vitro-transcribed RNAs were generated using standard approaches (1), with the inclusion of 32P-labeled CTP to generate radiolabeled probes. Radiolabel was omitted and higher substrate concentrations were used to produce recovery marker RNA. Recovery marker was included in experiments presented in Fig. 2, 3A, and 3C. Recovery marker was not added to RNA samples for experiments in Table 1 and Fig. 3B, where the only required measurement was the ratio of escort and GPP-type RNAs.

FIG. 2.

FIG. 2

Replication efficiencies of native-length and lengthened genomes. (A and B) Puromycin-resistant CFU per unit volume of virus-containing culture medium harvested from ET cells transiently transfected with equimolar amounts of vector expression plasmids, normalized to the value obtained for the parental pGPP plasmid. In experiments that included the pΨ+hyg escort plasmid, equimolar pΨ+hyg was added in place of some of the carrier DNA used in the no-pΨ+hyg transfections. (C and D) Puromycin-resistant CFU per unit of virion protein in the culture medium. (E and F) Packaging of viral RNA per unit virion protein in the presence and absence of Ψ+hyg escort RNA. (G and H) Puromycin-resistant CFU per unit of virion RNA in the presence and absence of Ψ+hyg escort RNA. The values in panel B were normalized to the GPP value in panel A. For all other panels, values presented were normalized to values obtained for the parental GPP vector in that panel and were determined from data such as those in Fig. 3, using approaches described in Materials and Methods. In panels E through H, “encapsidated RNA” refers to GPP, GPP derivative, or ΨMLV RNA and does not include Ψ+hyg escort RNA.

FIG. 3.

FIG. 3

RNase protection assays to quantify vector RNAs. (A) Assays of RNAs harvested from the culture medium of ET cells cotransfected with pGPP or related plasmid and pΨ+hyg. Lanes: 1, size standards; 2, undigested probe; 3, no sample or recovery marker control; 4, mock-transfected ET medium RNA; 5 to 10, RNA samples purified from the virion-containing culture media from cells transfected with pGPP+4, pGPP+8, pGPP+11, pGPP, pΨMLV, and pNCA (an infectious M-MLV provirus clone), respectively. Migration positions of protected bands diagnostic of each product are indicated at the right. U, undigested probe; G, GPP-type product; E, escort product; RM, recovery marker. (B) Assays of intracellular RNAs harvested from transfected cells. Designations at the top indicate which RNA is analyzed in each lane of panels B and C. (C) Assays of RNAs harvested from the culture medium of ET cells transfected with pGPP or related plasmid in the absence of pΨ+hyg.

TABLE 1.

Relative prevalence and packaging of large and escort RNAs

Cotransfected large vector plasmid Ratio, large/Ψ+hyg (mean ± SD)
Packaging factorb
Cellular RNA Virion RNA
pGPP 0.78 ± 0.01 0.73 ± 0.02 0.94
pGPP+4 0.65 ± 0.11 0.36 ± 0.06 0.55
pGPP+8 0.59 ± 0.01 0.29 ± 0.00 0.49
pGPP+11 0.55 ± 0.01 0.33 ± 0.02 0.60
pNCA (M-MLV)a 0.77 0.71 0.92
MLV 0.79 ± 0.01 0.07 ± 0.01 0.08
a

Values for wild-type M-MLV (pNCA) were determined only once. 

b

Defined as the ratio of virion RNA large/Ψ+hyg divided by cellular RNA large/Ψ+hyg. 

(iii) RNase protection assays.

Viral and cellular RNA and radiolabeled RNA probes were prepared as indicated above, and the same amount of RNA probe, which exceeded the total amount of sample to be protected by a molar factor of 5 to 50, was used for all samples within each experiment. Samples were hybridized, digested with RNases A and T, processed, and separated on 5% polyacrylamide–8 M urea gels by using standard techniques (1). Dried gels were exposed to film and/or analyzed with a Molecular Dynamics PhosphorImager and ImageQuant software. In experiments where molar ratios were determined, each band's intensity as measured by PhosphorImager was divided by the number of C residues (C was the radiolabeled substrate) in the protected probe fragment before comparing values for that band to those for others.

For cellular RNA blots, ET cells which stably expressed escort RNA were transfected with pGPP or derivatives and RNA was processed as above. RNA was separated on 0.7% formaldehyde-agarose gels, gels were washed, products were transferred to Hybond-N membranes (Amersham) by capillary action, and membranes were cross-linked in a Stratalinker (Stratagene), using standard approaches. Prehybridization and hybridization were conducted in 25 ml of 5× SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate)–5× Denhardt's solution–50% (wt/vol) formamide–1% (wt/vol) SDS at 65°C. Boiled herring sperm DNA was added to 100 μg/ml along with radiolabeled probe prepared using a random-primed DNA labeling kit from BMB or Redi-Prime kit from Amersham. EcoRI-linearized pD1040-2 was used to make RNA blot probes, while puromycin resistance or dystrophin gene fragments were used to make probes for DNA blots.

For viral RNA blots, two 6-cm-diameter plates of ET cells which stably expressed escort were calcium phosphate transfected with equimolar amounts of each of the pGPP series plasmids, and virus was collected at 12-h intervals for 2 days and then pooled. Viral RNA was prepared as described for RNase protection assays and analyzed as described for cellular RNA blots.

For Southern blots, genomic DNA was harvested using a Wizard genomic DNA purification kit (Promega). This DNA, which contained integrated proviruses, was restriction digested, separated on 0.7% agarose gels, blotted, and probed using standard procedures (1). Probes were random-primed DNA fragments labeled as above. Probes used for the Fig. 6 blots were a BamHI-ClaI puromycin gene fragment from pBabe-puro (21) (Fig. 6A and C) and a mixture of three dystrophin gene fragments from pGPP+11 (the 8.5- and 2.4-kb EcoRI fragments and the 1.5-kb DraI fragment) (Fig. 6B).

FIG. 6.

FIG. 6

Southern blot analysis of individual proviral products of the GPP+11 vector. (Top) Schematic drawing of a GPP+11 provirus showing the locations of restriction sites used to assess provirus sizes. Because of the template switches during reverse transcription, MLV-based vector DNAs should be 0.6 kb longer than their RNA templates (11). ClaI restriction sites and the size (10.5 kb) of the ClaI restriction fragment predicted for an unrearranged GPP+11 provirus are indicated, as are BstEII site locations and the sizes predicted for BstEII digestion (2.7, 3.2, and 6.3 kb). Drawing is not to scale. For abbreviations, see the legend to Fig. 1. (Bottom) Southern blot analyses of integrated vector proviruses. (A) GPP+11 clonal integrants that contain dystrophin region deletions digested with ClaI. Lanes: 1, size standards; 2, mock-infected cell DNA; 3 to 6, individual clonal integrants. (B) Candidate full-length GPP+11 GM integrant DNA analyzed with BstEII. Lanes: 1, size standards; 2, mock-infected cell DNA; 3, clone 4-8 DNA. (C) Restriction analysis of GPP+11 vector product sizes after a second round of replication. D17 clone DNAs were digested with ClaI. Lanes: 1, marker; 2, mock-infected D17 cellular DNA; 3, second-round product generated by clone 16-6; 4 to 6, second-round products from 4-4, 4-8, and 4-14, respectively; 7, size standards. Mobilities of DNA size standards are indicated at the left. For each panel, arrows indicate provirus-specific products and Δ indicates host-derived products detectable in both mock-infected and transduced cells. First-replication-round products were analyzed in 3T3 cells that express GaLV Env; second-round products were analyzed in D17 cells.

Except where indicated, numerical values presented for RNAs, proteins, and titers reflect results from at least two experimental repetitions of each quantification procedure for each of at least two completely independent transfection experiments.

RESULTS

Construction of large RNA genomes and small escort RNAs.

The goal of this study was to assess effects of retroviral genome length on RNA packaging and other replication steps. In the approach used, both the encapsidated RNAs and all proteins necessary for the production of virions were encoded by single expression plasmids. The parental expression plasmid, pGPP, was an M-MLV provirus plasmid in which the splice donor site was inactivated and the env coding region was replaced with a puromycin resistance expression cassette (27) (Fig. 1). This vector encodes an 8.1-kb viral RNA, which is essentially the same length as the native MLV genome (8.2 kb).

FIG. 1.

FIG. 1

Structures of proviral clones and other constructs. Virus coding regions are presented as shaded boxes. Restriction sites indicated below pGPP+11 are those used to map reverse transcription products in Fig. 6. The viral sequences in pD1040-2, an RNA probe expression plasmid, are represented by a shaded box. PSV40, simian virus 40 promoter; LTR, long terminal repeat; Ψ+, packaging site; Δ, deletion of packaging site.

We generated lengthened derivatives of pGPP (Fig. 1) that contained fragments of murine dystrophin cDNA inserted between pol and the puromycin resistance gene cassette. Inserts of 3.9, 7.9, and 11.1 kb were made to yield pGPP+4, pGPP+8, and pGPP+11, which are predicted to produce viral RNAs 12, 16, and 19.2 kb in length, respectively. pΨ+hyg, a plasmid that encodes a short packageable RNA, was also constructed to test the ability of short RNAs to heterodimerize with long viral RNAs and facilitate their encapsidation (Fig. 1). Reflecting this postulated role of Ψ+hyg RNA, this short vector is herein referred to as an escort RNA. pΨ+hyg is a splice donor-defective derivative of an MLV provirus plasmid which contains a hygromycin B phosphotransferase expression cassette in place of the viral coding sequences, followed by the herpes simplex virus polyadenylation signal. Blotting analysis revealed that expression of pΨ+hyg yielded intracellular RNAs of the predicted ∼3.1-kb length (data not shown).

The rationale for using a single construct to express both virion proteins and genomic RNA was as follows. If an alteration to GPP did not affect packaging, then when that GPP derivative was expressed in mammalian cells, the relative amounts of RNA which would be directed to mRNA and to encapsidated genome functions would remain the same as for the parental GPP vector. In contrast, if changes introduced into a GPP derivative caused RNA encapsidation defects, then the amount of RNA per unit of viral protein in extracellular virions would decrease. Hence, comparing the molar amount of vector RNA per unit extracellular virion protein of the GPP vector to values for its derivatives would provide a way of examining effects on encapsidation.

Relative replication efficiency of large and small genomes.

As an initial test of these vectors' ability to support a single replication cycle, pGPP and its derivatives were transfected into ET cells, which are human 293T-derived cells that stably express ecotropic Env (27), and the resulting virion titers were determined. Equimolar amounts of each pGPP-type plasmid were transfected into ET cells. Parallel experiments aimed at examining the effects of the Ψ+hyg escort RNA were also performed by transfecting secondary plates of ET cells with the same amounts of pGPP-type plasmids supplemented with equimolar pΨ+hyg. Fresh murine cells were then infected with an equal volume of each virus stock, and puromycin-resistant colony titers were determined.

Results from two such experiments are presented in Fig. 2A and B. Titers are presented as puromycin-resistant CFU per volume of virus-containing medium, standardized to the titer for the parental GPP expressed in the absence of Ψ+hyg. The titer of the parental vector was roughly 104 puromycin-resistant CFU/ml. These initial trials demonstrated that product titers were around 5- to 10-fold lower for large retroviral vectors than for native-length ones generated in experiments where virus was produced from transiently transfected cells. A comparison of the data in Fig. 2A (no pΨ+hyg) and 2B (cotransfection with pΨ+hyg) indicates that Ψ+hyg did not increase the puromycin-resistant CFU of long vectors and may have decreased titers slightly. This finding appears to be inconsistent with the initial hypothesis that Ψ+hyg might enhance packaging and the generation of proviral products when coexpressed with lengthy viral RNAs. Note that although the lengthened genomes all yielded lower titers than native-length GPP, there were no consistent size-related trends in apparent replication efficiency among lengthened genomes (GPP+4, GPP+8, and GPP+11). Titers normalized to the amount of virion protein in the culture medium are presented in Fig. 2C and D. As assessed by levels of virus protein in the culture medium, the amount of virus produced by cells transfected with larger vector plasmids was slightly (less than twofold) lower than the amount produced by cells transfected with the parental pGPP. Whether this nominal but reproducible decrease in virion protein release from transfected cells resulted from reduced transfection efficiency for large plasmids or an effect on viral replication was not determined.

Assessing packaging biases between large and small genomes.

The stoichiometries of Ψ+hyg and GPP-type RNAs within cotransfected cells were compared to their ratios in virions. The value which described the molar amount of large GPP-type vector RNA per Ψ+hyg RNA in virions relative to intracellular stoichiometries of these two RNAs is referred to as the packaging factor. It was assumed that if an RNA were defective in packaging, then it would be less prevalent relative to Ψ+hyg in virions than in producer cells. Although no attempt was made to determine whether proteins were limiting or RNA was expressed at saturating concentrations, these measurements were interpreted as addressing the ability of the lengthened RNAs to compete with short RNAs for the packaging machinery.

The data were generated by cotransfecting ET cells with equimolar amounts of pΨ+hyg and pGPP or its derivatives and then determining RNA ratios in both cells and virions by RNase protection assays. The RNase protection probe spanned the junction of sequences that the GPP vectors share with the Ψ+hyg escort and sequences in which they differ (Fig. 1, pD1040-2). Thus, a single probe could be used to detect both long vector and short escort RNAs as protected products of distinct sizes, and the molar ratios of the two RNAs could be determined by the ratios of these protected bands. In experiments that addressed RNA packaging in the absence of Ψ+hyg, packaging biases were examined by determining how much RNA was encapsidated per unit of extracellular virion protein. Because quantifying virion RNAs required several purification steps, viral RNA recovery was monitored by introducing an RNA recovery marker early during virion RNA purification and then normalizing values based on the amount of recovery marker in the final product. The recovery marker was a nonradiolabeled in vitro transcript complementary to a short portion of the same RNase protection probe used to detect Ψ+hyg and GPP RNAs.

Figure 3 shows the results of RNase protection assays performed on cellular and virion RNA harvested from producer cells transfected with pGPP or related plasmid in the presence or absence of pΨ+hyg. The intracellular ratios of Ψ+hyg and each larger coexpressed RNA, the ratios of these two types of RNAs within virions, and the ratios of these two values (the packaging factor) are presented in Table 1. These values were not corrected for virion numbers but instead describe the relative amounts of the indicated RNAs. Controls were performed in which a wild-type MLV provirus plasmid (pNCA) (6) or a packaging-defective provirus plasmid (pΨMLV [27]) was cotransfected with pΨ+hyg. As anticipated, encapsidation of Ψ packaging mutant RNAs was strongly disfavored relative to Ψ+hyg RNAs (Table 1, pΨMLV). The relative prevalence of the parental GPP RNA and the Ψ+hyg escort in virions was very similar to that observed intracellularly, suggesting that GPP and Ψ+hyg were equally fit for encapsidation. In contrast, modest biases against packaging were observed for the dystrophin-containing lengthened GPP derivative RNAs, with each of these long RNAs around half as prevalent in virions as in cells relative to the amounts of Ψ+hyg (Table 1).

To address the contribution of Ψ+hyg to this fairly efficient encapsidation of long RNAs, levels of large RNAs in virions produced both in the presence and in the absence of Ψ+hyg were compared. An RNase protection assay of virion RNAs produced in the absence of Ψ+hyg is shown in Fig. 3C. Amounts of viral RNA per unit virion proteins in the presence and in the absence of Ψ+hyg escort are compared in Fig. 2E and F. These data suggest that coexpression of the short Ψ+hyg escort RNA did not facilitate long vector packaging.

Examining viral RNAs designed to exceed wild-type length.

As assayed above, long vector packaging appeared to be reduced less than twofold relative to the native-length vector, while titers per unit virion protein were decreased roughly four- or fivefold. It seemed possible that some component of the decreased titer per unit RNA for the lengthened GPP derivatives might have resulted if more of the RNAs were incomplete in long vector virions than in those of native-length vectors. For the data shown in Fig. 2E through H, RNAs were quantified by RNase protection assays that used a probe complementary to a short portion of RNA near 5′ ends of the genomes, and no attempt was made to determine the amount of 3′ RNA sequences. Thus, to assess whether virions may have differed in full-length RNA content, RNase protection assays were performed on virion RNAs, using excess amounts of two different probes in each reaction. One probe was complementary to sequences near the 5′ ends of the RNAs, and the other was complementary to puromycin gene sequences near the 3′ ends. The results (Fig. 4) were quantified by a PhosphorImager. The molar amount of each product was determined as described in Materials and Methods, and then the molar ratios of the 5′ and 3′ portions of the RNAs were compared. For GPP, the determined molar ratio of 5′ to 3′ ends was 1.01; for GPP+4, the ratio was 0.98; for GPP+8, it was 1.16; and for GPP+11, the ratio was 1.29. Thus, the molar ratio of 5′ and 3′ ends for native-length GPP did not differ greatly from values for its lengthened derivatives. Similar results were obtained when a single probe derived from the long terminal repeat which protected both 5′ and 3′ sequences, was used.

FIG. 4.

FIG. 4

RNase protection assay of 5′ and 3′ ends of GPP-type RNAs. Lanes: 1, size standards; 2, undigested 3′ (puro) probe; 3, undigested 5′ (gag) probe; 4, probe-alone control; 5, mock-transfected ET medium RNA; 6 to 10, RNA samples from the virion-containing culture media from cells transfected with pGPP, pGPP+4, pGPP+8, pGPP+11, and pNCA (which expresses wild-type MLV), respectively. Migration positions of undigested probes and protected bands diagnostic of each product are indicated at the right.

Because results in Fig. 4 did not differentiate between whether full-length RNAs were packaged or if virions contained shortened RNAs generated by the use of cryptic splice sites or other unintended genome modifications, Northern blots were used to assess viral RNA lengths both in virus-producing cells and in extracellular virions. Figure 5A shows a blot of total cellular RNA from cells expressing the GPP derivatives probed with a fragment of gag. To assess RNA lengths, samples were heat denatured and separated on denaturing gels. Using the mobilities of Ψ+hyg and wild-type MLV RNA as size standards, this blot shows that RNAs of roughly the predicted lengths were generated in cells expressing GPP derivatives. Data for virion RNAs are shown in Fig. 5B. At least some of the encapsidated RNAs for each vector appeared to be of the full intended length, but significant smears of faster-mobility material were also detected. There were no detectable discrete-length RNAs among these shorter products, suggesting that the virion RNA was not dominated by specific unintended spliced RNAs.

FIG. 5.

FIG. 5

Denaturing Northern blots of vector RNAs. (A) Cellular RNA extracted from ET cells transfected with pGPP and derivative plasmids. Two amounts of RNA were loaded for each sample so that the odd-numbered lanes contain 2.5-fold as much sample as the even-numbered lanes. RNA was from cells expressing GPP (lanes 1 and 2), GPP+4 (lanes 3 and 4), GPP+8 (lanes 5 and 6), and GPP+11 (lanes 7 and 8). (B) Virion RNA harvested from the culture medium of ET cells transfected as above. Lanes: 1, GPP; 2, GPP+4; 3, GPP+8; 4, GPP+11. Numbers at the right indicate the mobilities of RNA size standards of the indicated lengths in kilobases. The identity of the faster-migrating band in lanes 1 and 2 of panel A was not determined.

Effects of genome length on efficiency of postpackaging steps.

Having obtained data suggesting that packaging defects were fairly modest, it seemed possible that some of the observed titer decreases for long genomes might reflect defects in postpackaging steps of the viral replication cycle. Size-related defects might include disrupting maturation of viral particles or RNA (9), altering the stoichiometry of putative accessory factors such as nucleocapsid (7), perturbing the higher-order structure required for reverse transcription (17), or interfering with the sustained synapsing of viral DNA ends required for integration (22).

To address whether length-related limitations were imposed during early stages of retroviral replication, the titer of puromycin-resistant proviruses formed per unit of encapsidated RNA were compared for parental GPP and for GPP+4, GPP+8, and GPP+11. The results (Fig. 2G and H) indicate that all of the lengthened vectors generated roughly threefold-fewer colonies per mole of encapsidated RNA than did parental GPP.

Proviral DNAs templated by lengthened vectors.

Clonal integrated proviruses generated from GPP-type vectors were examined by Southern blotting. The restriction digests used to analyze these proviruses are indicated at the top of Fig. 6, and some of the blots used to analyze clonal GPP+11 integrants are displayed below. Figure 6A shows a blot of ClaI digests of genomic DNA from several individual GPP+11 proviral clones which contained shorter-than-anticipated dystrophin segments. As indicated at the top of Fig. 6, an intact GPP+11 provirus would be predicted to yield a 10.5-kb band detectable on these blots. Note that ClaI fragments detected for the GPP+11 integrants analyzed in Fig. 6A varied in length, with several appearing to have products of the same altered mobility (Fig. 6A, lanes 4 to 6). The frequent occurrence of similar-sized products suggests that these may have had a common origin such as an ∼2-kb deletion which resulted from unintended splicing or from a hot spot for recombination during reverse transcription. Genomic rearrangements such as deletions and insertions frequently arise during reverse transcription (25, 28). Figure 6B shows results of BstEII digestion of a GPP+11 provirus whose ClaI fragment appeared to be full length. The observed restriction fragments of 6.3, 3.2, and 2.7 kb that are detectable with dystrophin probes are consistent with the sizes predicted for a full-length 19.8-kb provirus. Overall, these results suggest that most products of GPP+11 contained deletions after a single round of replication.

Because GPP vectors contain gag and pol sequences, a second round of replication was possible when virions shed by cells transduced with GPP proviruses were provided Env. This was accomplished by infecting 3T3 cells that expressed GaLV Env as the endpoint of the first replication round (see Materials and Methods) and then infecting fresh D17 cells with virions produced by these cells. Integrated products of some GPP+11 proviruses generated during a second round of replication were examined by Southern blotting (Fig. 6C). Among the GPP+11 products, proviruses which were 12.8 and 14.3 kb long after the first replication round generated progeny which appeared to maintain these lengths on secondary passage (Fig. 6C, lanes 3, 4, and 6), but the tested product of a full-length 19.8 kb provirus was reduced to an apparent length of 16.0 kb during a second replication round (Fig. 6C, lane 5).

Similar approaches were used to examine clonal GPP+4 and GPP+8 integrants (data not shown). All four GPP+4 progeny proviruses tested appeared to be full length, as did two of four GPP+8 integrants. In addition to the two GPP+8 integrants that yielded the restriction patterns predicted for unrearranged proviruses, one yielded a ClaI fragment approximately 2 kb longer than predicted for a full-length GPP+8 product, and the fourth contained a ClaI fragment about 2.3 kb shorter than predicted.

DISCUSSION

In this report, the packaging efficiencies of native-length retroviral RNAs were compared to those of RNAs significantly longer than wild type. The ability of lengthy RNAs to compete with short RNAs for the MLV packaging machinery and the ability of long genomes to participate in subsequent replication steps were examined. Overall, replication of lengthened genomes was reduced 5- to 10-fold relative to native-length genomes. This reduction was the product of modest defects in virion production and in packaging, and somewhat greater defects in subsequent stages, with large vector replication not absolutely restricted at any one stage. RNAs twice the natural genome length could become encapsidated and could template integration-competent DNA. Although many of the resulting proviruses contained detectable defects such as deletions, in some cases, progeny proviruses were able to form infectious particles that could complete a subsequent round of replication. These findings demonstrate that large genome replication is impaired at several stages but that there are no absolute size restrictions against genomes twice the normal length at any stage of the MLV replication cycle.

A premise of this study had been that dimers of lengthy RNAs would be excluded from packaging. Therefore, in some experiments, a short packageable RNA, Ψ+hyg, was coexpressed with the lengthy vectors to test whether short RNA might facilitate long RNA packaging by heterodimerization. Surprisingly, long RNAs were packaged fairly well even in the absence of the Ψ+hyg. No augmentation of lengthy RNA packaging was observed in the presence of the Ψ+hyg escort.

Some of the observed titer decrease for long genomes may have reflected a decrease in the amount of intact template RNA for lengthy vectors. Most lengthy vector virion RNAs did not appear intact on Northern blots, but it is not uncommon for virion RNA to appear degraded (5). This apparently is particularly an issue for denatured RNAs like those analyzed in this report, because several groups have published data showing fairly discrete bands for nondenatured retroviral RNA but smears when the same virion-associated RNAs were denatured (8, 18, 24). Note, however, that the presence of sequences encompassing the full length of the RNAs would be required to template full-length proviral DNAs. Thus, the observation here that some full-length proviruses were generated implies that at least some virions encapsidated the entire length of the RNAs, even for the longest genomes.

How can the finding that lengthy genomes can complete a replication cycle be reconciled with previous findings regarding the rapid loss of insertions in replication-competent retroviruses? Most likely, the key difference is that the present experiments examined a single replication cycle and hence selective advantages were not assessed. As retroviruses replicate, individual viruses with relatively modest survival advantages can come to dominate populations rapidly (4). In previously reported experiments, the inserted sequences did not benefit virus replication (10, 34) and may even have been lost for the simple reason that they increased genome length and thus the time required for replication. Many types of viruses generate deletion-containing defective interfering particles during undiluted virus passage, and coding region-deleted genomes are detectable in retroviral cultures during passage at high multiplicity of infection (3, 33, 39, 40). It has long been recognized that retroviral sequences that do not provide a selective advantage, as is the case for src in culture-adapted RSV, are prone to deletion even with a low multiplicity of infection (38). It seems likely that the nonessential dystrophin insertions studied here would be lost rapidly if the vectors replicated freely.

Regardless of their fates during sustained replication, this demonstration of the packageability of long RNAs has important ramifications for rare retroviral replication events. For example, some models for how retroviruses transduce cellular oncogenes envision initial capture of the host gene as resulting from proviral insertion near or within a host proto-oncogene (35, 36, 42). To conform with prevailing notions of packaging limits, transduction models generally go on to postulate either a DNA-level deletion of the downstream long terminal repeat or aberrant splicing of a read-through RNA to prune a chimeric virus-host RNA to a packageable length. The finding in this report of the encapsidation of RNAs more than twice the native length demonstrates that lengthy read-through RNAs could be packaged directly without further processing.

A possible practical application of encapsidating large retroviral genomes would be the formation of longer integrated proviruses from retroviral vectors. For such applications, only a single replication cycle is generally required, and so competitive disadvantage would not affect the outcome. However, the significant rate of errors observed among product DNAs suggests that such large vectors would be useful only in protocols that allowed screening of several integrants to identify ones that had maintained integrity.

Many questions remain unanswered. Were the lengthy vectors encapsidated as homodimers? As monomers? Might even the “unescorted” vectors have become encapsidated in partnership with fortuitously 3′ truncated RNAs? Do coexpressed RNAs randomly copackage, or do biases for or against copackaging of nonhomologous RNAs exist? With the 19.2-kb vectors, has the upper size limit of packageable RNAs been reached or can even longer RNAs be encapsidated? Further study is required to address these and related questions.

ACKNOWLEDGMENTS

We thank Maribeth Eiden for providing GaLV env, Jeffrey Chamberlin for providing dystrophin cDNA, and Oveta Fuller and Thomas Glaser for other reagents. We thank Nancy Sullivan and M. J. Wieland for critical reading of the manuscript and the anonymous reviewers whose comments improved the final version. We also thank David Rekosh and Alan Engleman for advice and Heidi Ackerly, Deanna Kulpa Stom, and the Horace H. Rackham School of Graduate Studies for assistance and support in early stages of this project.

This research was supported by NIH grant CA69300 and by the Searle Scholars program of the Chicago Community Trust.

REFERENCES

  • 1.Ausubel F M, Brent R, Kingston R E, Moore D D, Smith J A, Struhl K, editors. Current protocols in molecular biology. New York, N.Y: John Wiley & Sons, Inc.; 1994. [Google Scholar]
  • 2.Berkowitz R, Fisher J, Goff S P. RNA packaging. Curr Top Microbiol Immunol. 1996;214:177–218. doi: 10.1007/978-3-642-80145-7_6. [DOI] [PubMed] [Google Scholar]
  • 3.Clever J L, Parslow T G. Mutant human immunodeficiency virus type 1 genomes with defects in RNA dimerization or encapsidation. J Virol. 1997;71:3407–3414. doi: 10.1128/jvi.71.5.3407-3414.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Coffin J M. Genetic diversity and evolution of retroviruses. Curr Top Microbiol Immunol. 1992;176:143–164. doi: 10.1007/978-3-642-77011-1_10. [DOI] [PubMed] [Google Scholar]
  • 5.Coffin J M. Structure, replication, and recombination of retrovirus genomes: some unifying hypotheses. J Gen Virol. 1979;42:1–26. doi: 10.1099/0022-1317-42-1-1. [DOI] [PubMed] [Google Scholar]
  • 6.Colicelli J, Goff S P. Sequence and spacing requirements of a retrovirus integration site. J Mol Biol. 1988;199:47–59. doi: 10.1016/0022-2836(88)90378-6. [DOI] [PubMed] [Google Scholar]
  • 7.Darlix J-L, Yu C, Berthoux L, Ottmann M, Jullian N, Roques B. La nucleocapside du VIH-1: un paradigme pour la recherch et ses applications medicales. Med Sci. 1995;11:420–429. [Google Scholar]
  • 8.Fu W, Gorelick R J, Rein A. Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and protease-defective virions. J Virol. 1994;68:5013–5018. doi: 10.1128/jvi.68.8.5013-5018.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Fu W, Rein A. Maturation of dimeric viral RNA of Moloney murine leukemia virus. J Virol. 1993;67:5443–5449. doi: 10.1128/jvi.67.9.5443-5449.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Gelinas C, Temin H M. Nondefective spleen necrosis-derived vectors define the upper size limit for packaging reticuloendotheliosis viruses. Proc Natl Acad Sci USA. 1986;83:9211–9215. doi: 10.1073/pnas.83.23.9211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Gilboa E, Mitra S W, Goff S P, Baltimore D. A detailed model of reverse transcription and tests of crucial aspects. Cell. 1979;18:93–100. doi: 10.1016/0092-8674(79)90357-x. [DOI] [PubMed] [Google Scholar]
  • 12.Hall C V, Jacob P E, Ringold G M, Lee F. Expression and regulation of Escherichia coli lacZ gene fusions in mammalian cells. J Mol Appl Genet. 1983;2:101–109. [PubMed] [Google Scholar]
  • 13.Hartman S C, Mulligan R C. Two dominant-acting selectable markers for gene transfer studies in mammalian cells. Proc Natl Acad Sci USA. 1988;85:8047–8051. doi: 10.1073/pnas.85.21.8047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Herman S A, Coffin J M. Efficient packaging of readthrough RNA in ALV: implications for oncogene transduction. Science. 1987;236:845–848. doi: 10.1126/science.3033828. [DOI] [PubMed] [Google Scholar]
  • 15.Holzschu D L, Martineau D, Fodor S K, Vogt V M, Bowser P R, Casey J W. Nucleotide sequence and protein analysis of a complex piscine retrovirus, walleye dermal sarcoma virus. J Virol. 1995;69:5320–5331. doi: 10.1128/jvi.69.9.5320-5331.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Jones J S, Allan R W, Seufzer B, Temin H M. Copackaging of different-sized retroviral genomic RNAs: little effect on retroviral replication or recombination. J Virol. 1994;68:4097–4103. doi: 10.1128/jvi.68.6.4097-4103.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Jones J S, Allan R W, Temin H M. One retroviral RNA is sufficient for synthesis of viral DNA. J Virol. 1994;68:207–216. doi: 10.1128/jvi.68.1.207-216.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Lear A L, Haddrick M, Heaphy S. A study of the dimerization of Rous sarcoma virus RNA in vitro and in vivo. Virology. 1995;212:47–57. doi: 10.1006/viro.1995.1452. [DOI] [PubMed] [Google Scholar]
  • 19.Lee C C, Pearlman J A, Chamberlain J S, Caskey C T. Expression of recombinant dystrophin and its localization to the cell membrane. Nature. 1991;349:334–336. doi: 10.1038/349334a0. [DOI] [PubMed] [Google Scholar]
  • 20.Miller A D. Development and applications of retroviral vectors. In: Coffin J M, Hughes S H, Varmus H E, editors. Retroviruses. Plainview, N.Y: Cold Spring Harbor Laboratory Press; 1997. pp. 437–473. [PubMed] [Google Scholar]
  • 21.Morgenstern J P, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 1990;18:3587–3596. doi: 10.1093/nar/18.12.3587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Murphy J E, Goff S P. A mutation at one end of Moloney murine leukemia virus DNA blocks cleavage of both ends by the viral integrase in vivo. J Virol. 1992;66:5092–5095. doi: 10.1128/jvi.66.8.5092-5095.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Nevins J R, Vogt P K. Cell transformation by viruses. 1996. p. 27. =67–310. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fundamental virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa. [Google Scholar]
  • 24.Ortiz-Conde B A, Hughes S H. Studies of the genomic RNA of leukosis viruses: implications for RNA dimerization. J Virol. 1999;73:7165–7174. doi: 10.1128/jvi.73.9.7165-7174.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Pathak V K, Temin H M. Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: deletions and deletions with insertions. Proc Natl Acad Sci USA. 1990;87:6024–6028. doi: 10.1073/pnas.87.16.6024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Petropoulos C J, Hughes S H. Replication-competent retrovirus vectors for the transfer and expression of gene cassettes in avian cells. J Virol. 1991;65:3728–3737. doi: 10.1128/jvi.65.7.3728-3737.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Pfeiffer J K, Topping R, Shin N-H, Telesnitsky A. Altering the intracellular environment increases the frequency of tandem repeat deletion during Moloney murine leukemia virus reverse transcription. J Virol. 1999;73:8441–8447. doi: 10.1128/jvi.73.10.8441-8447.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Preston B D, Dougherty J P. Mechanisms of retroviral mutation. Trends Microbiol. 1996;4:16–21. doi: 10.1016/0966-842x(96)81500-9. [DOI] [PubMed] [Google Scholar]
  • 29.Price J, Turner D, Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA. 1987;84:156–160. doi: 10.1073/pnas.84.1.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Rein A. Retroviral RNA packaging: a review. Arch Virol Suppl. 1994;9:513–522. doi: 10.1007/978-3-7091-9326-6_49. [DOI] [PubMed] [Google Scholar]
  • 31.Robson N D, Telesnitsky A. Effects of 3′ untranslated region mutations on plus-strand priming during Moloney murine leukemia virus replication. J Virol. 1999;73:948–957. doi: 10.1128/jvi.73.2.948-957.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Sakalian M, Wills J W, Vogt V M. Efficiency and selectivity of RNA packaging by Rous sarcoma virus gag deletion mutants. J Virol. 1994;68:5969–5981. doi: 10.1128/jvi.68.9.5969-5981.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Sakuragi J-I, Panganiban A. Human immunodeficiency virus type 1 RNA outside the primary encapsidation and dimer linkage region affects RNA dimer stability in vivo. J Virol. 1997;71:3250–3254. doi: 10.1128/jvi.71.4.3250-3254.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Stuhlmann H, Jaenisch R, Mulligan R C. Construction and properties of replication-competent murine retroviral vectors encoding methotrexate resistance. Mol Cell Biol. 1989;9:100–108. doi: 10.1128/mcb.9.1.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Sugden B. How some retroviruses got their oncogenes. Trends Biochem Sci. 1993;18:233–235. doi: 10.1016/0968-0004(93)90168-m. [DOI] [PubMed] [Google Scholar]
  • 36.Swain A, Coffin J M. Mechanism of transduction by retroviruses. Science. 1992;255:841–845. doi: 10.1126/science.1371365. [DOI] [PubMed] [Google Scholar]
  • 37.Tybulewicz V L, Crawford C E, Jackson P K, Bronson R T, Mulligan R C. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 1991;65:1153–1163. doi: 10.1016/0092-8674(91)90011-m. [DOI] [PubMed] [Google Scholar]
  • 38.Vogt P K. Historical introduction to the general properties of retroviruses. In: Coffin J M, Hughes S H, Varmus H E, editors. Retroviruses. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory; 1997. pp. 1–25. [PubMed] [Google Scholar]
  • 39.von Magnus P. Incomplete forms of influenza virus. Adv Virus Res. 1954;2:59–79. doi: 10.1016/s0065-3527(08)60529-1. [DOI] [PubMed] [Google Scholar]
  • 40.Voynow S L, Coffin J M. Evolutionary variants of Rous sarcoma virus: large deletion mutants do not result from homologous recombination. J Virol. 1985;55:67–78. doi: 10.1128/jvi.55.1.67-78.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Wilson C, Reitz M S, Okayama H, Eiden M V. Formation of infectious hybrid virions with gibbon ape leukemia virus and human T-cell leukemia virus retroviral envelope glycoproteins and the Gag and Pol proteins of Moloney murine leukemia virus. J Virol. 1989;63:2374–2378. doi: 10.1128/jvi.63.5.2374-2378.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Zhang J, Temin H M. 3′ junctions of oncogene-virus sequences and the mechanisms for formation of highly oncogenic retroviruses. J Virol. 1993;67:1747–1751. doi: 10.1128/jvi.67.4.1747-1751.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES